Gilead and Arcellx presented updated data indicating their cell therapy anito-cel for multiple myeloma maintains a favorable safety profile compared to competitors, while delivering comparable efficacy. Their findings released at EHA 2025 suggest improved tolerability over Legend Biotech and Johnson & Johnson’s Carvykti. These results support the potential for safer immunotherapy options in treating multiple myeloma, a complex hematologic malignancy.